Thymogen is a Khavinson immune peptide bioregulator — the synthetic dipeptide L-Glutamyl-L-Tryptophan (Glu-Trp, "EW"), a thymus-derived immunomodulator also sold as "Thymagen." It has a defined chemical identity (PubChem CID 100094).
Khavinson immune peptide bioregulator; synthetic dipeptide Glu-Trp (EW). Single compound.
Thymogen is a dipeptide originally isolated from the calf-thymus peptide complex Thymalin and then synthesized. It acts as an immunomodulator: the literature describes activation of T-cell differentiation and T-cell recognition of peptide–MHC complexes, shifts in intracellular cyclic-nucleotide balance, and stimulation of neutrophil chemotaxis and phagocytosis. Like other Khavinson ultrashort peptides, it is proposed to act at very low concentrations as a regulatory/gene-expression signal in immune tissue.
Thymogen is one of the better-documented compounds in the Khavinson family, and its indexed literature is genuinely on-topic. It has a defined chemical identity (PubChem CID 100094) and a real pharmaceutical history: derived from Thymalin, synthesized in the late 1980s, and in Russian medical use as an immunomodulator since 1990. Recent peer-reviewed work (2023–2025) has examined Thymogen and its D-Ala analogues for hepatoprotective and antioxidant effects in rat liver-damage models, its chiral counterpart Thymodepressin (an immunosuppressant — the "reciprocal" activity), and its behavior among ultrashort regulatory peptides.
Epistemic caveat: even so, the evidence base is predominantly from the Khavinson tradition and Russian research/clinical practice. Western randomized controlled trials are absent; much of the efficacy record is animal-model or regional clinical use rather than independent RCT data.
In the double-blind, randomized, placebo-controlled study by Smirnov and colleagues (2011) in elderly patients undergoing surgery for abdominal and retroperitoneal solid tumors, Thymogen was administered by intranasal instillation once a day for 7 days before surgery (PubMed).
A registered immunomodulator in Russia (multiple dosage forms) but not FDA/EMA-approved; sold research-use-only in Western markets. Reported as well tolerated in its regional clinical history; no rigorous independent Western safety dataset. Note its chiral mirror Thymodepressin has the opposite (immunosuppressive) effect — chirality matters for this molecule.
Stronger than most Khavinson peptides — defined chemistry, a real immunomodulatory mechanism literature, recent analogue studies, and decades of regional clinical use. Still limited by the absence of Western RCTs and reliance on the Khavinson/Russian research tradition.
Thymogen = Glu-Trp dipeptide (a.k.a. Thymagen, EW); an immune-targeted Khavinson bioregulator derived from Thymalin. Distinguish from Thymalin (the parent thymus peptide complex), Thymodepressin (the chiral immunosuppressant), and Bestim (a more potent gamma-Glu-Trp analogue). Sold as injectable lyophilate and intranasal forms.
